Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

por Sonesson, Christian, Johansson, Peter A., Johnsson, Eva, Gause-Nilsson, Ingrid
Publicado 2016

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled...

por Cefalu, William T., Leiter, Lawrence A., de Bruin, Tjerk W.A., Gause-Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J.
Publicado 2015

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

por McEwan, Phil, Morgan, Angharad R., Boyce, Rebecca, Bergenheim, Klas, Gause‐Nilsson, Ingrid A.M., Bhatt, Deepak L., Leiter, Lawrence A., Johansson, Peter A., Mosenzon, Ofri, Cahn, Avivit, Wilding, John P.H.
Publicado 2021

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

por Mosenzon, Ofri, Wiviott, Stephen D., Heerspink, Hiddo J.L., Dwyer, Jamie P., Cahn, Avivit, Goodrich, Erica L., Rozenberg, Aliza, Schechter, Meir, Yanuv, Ilan, Murphy, Sabina A., Zelniker, Thomas A., Gause-Nilsson, Ingrid A.M., Langkilde, Anna Maria, Fredriksson, Martin, Johansson, Peter A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Sabatine, Marc S., Raz, Itamar
Publicado 2021

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

por Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D., Schechter, Meir, Goodrich, Erica L., Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A., Zelniker, Thomas A., Langkilde, Anna Maria, Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Johansson, Peter A., Wilding, John P.H., McGuire, Darren K., Bhatt, Deepak L., Leiter, Lawrence A., Cahn, Avivit, Dwyer, Jamie P., Heerspink, Hiddo J.L., Sabatine, Marc S.
Publicado 2022